NCT00624481

Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD

A Phase 2, 24-Week, Multicenter, Randomized, Parallel-Group, Dose-Ranging Study To Evaluate The Effect Of Teriparatide Nasal Spray On Bone Mineral Density In Postmenopausal Women With Low Bone Mineral Density

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 350 (estimated)
• Sponsor: Nastech Pharmaceutical Company, Inc. · Industry
• Sex: Female
• Age: 89 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to compare the effect of increasing nasal teriparatide dosing on percent change in Bone Mineral Density (BMD) of the lumbar spine after 24 weeks of therapy in postmenopausal women with low bone mineral density.

Conditions

• Osteopenia
• Osteoporosis

Interventions

Type	Name	Description
DRUG	Teriparatide	20ug subcutaneous injection daily for 24 weeks
DRUG	Teriparatide Nasal Spray	teriparatide intranasally daily for 24 weeks
DRUG	Teriparatide Nasal Spray	teriparatide intranasally daily for 24 weeks
DRUG	Teriparatide Nasal Spray	teriparatide intranasally daily for 24 weeks
DRUG	Teriparatide Nasal Spray	teriparatide intranasally daily for 24 weeks

Timeline

• Start date: 2008-03-01
• Primary completion: 2009-04-01
• Completion: 2009-04-01
• First posted: 2008-02-27
• Last updated: 2008-03-13